NewAmsterdam Pharma Reports Third Quarter Earnings Beat on Revenue and EPS
NewAmsterdam Pharma (NAMS) reported third-quarter financial results that exceeded analyst expectations for both earnings per share and revenue. The company posted a GAAP EPS of -$0.14, which outperformed estimates by $0.30, and recorded revenue of $19.16 million, surpassing projections by $4.11 million. This represents a significant year-over-year revenue increase of over 5,000%. Despite the earnings beat, the company's liquidity position saw a decline. As of September 30, 2026, NewAmsterdam reported cash, cash equivalents, and marketable securities totaling $643.1 million, down from $728.9 million at the end of December 2025.
Tickers: $NAMS
Topics: cash position earnings beat revenue growth